| Balance Sheets | 2026-06-30 | 2026-03-31 | 2025-12-31 | |
|---|---|---|---|---|
| Cash and cash equivalents | 11,542 | 3,080 | 5,143 | |
| Prepaid expenses | 270 | 389 | - | |
| Other current assets | - | 33 | 27 | |
| Total current assets | 11,812 | 3,502 | 5,170 | |
| Total assets | 11,812 | 3,502 | 5,170 | |
| Accounts payable | 683 | 850 | 470 | |
| Due to related party | 96 | 98 | 91 | |
| Accrued expenses related party | 73 | 45 | 23 | |
| Accrued expenses and other current liabilities | 21 | 21 | 21 | |
| Total current liabilities | 873 | 1,014 | 605 | |
| Total liabilities | 873 | 1,014 | 605 | |
| Common stock 0.0001 par value 560,000,000 shares authorized 49,845,993 and 47,343,297 shares issued and outstanding at june 30, 2026 and december 31, 2025, respectively | 5 | 5 | 5 | |
| Additional paid-in capital | 114,493 | 104,662 | 104,195 | |
| Accumulated deficit | -103,559 | -102,179 | -99,635 | |
| Total stockholders equity | 10,939 | 2,488 | 4,565 | |
| Total liabilities and stockholders equity | 11,812 | 3,502 | 5,170 | |
Polaryx Therapeutics, Inc. (PLYX)
Polaryx Therapeutics, Inc. (PLYX)